Uniting Forces: Addressing Needs in Blood Cancer Care

Every year around 300,000 EU citizens receive a diagnosis for a haematalogical malignancy, including leukaemia, lymphoma, multiple myeloma. Each cancer type places its own unique demands on health systems and how they can best prevent, detect, diagnose, and treat these diseases.

 

To this end, the European Cancer Organisation is supporting the EU-funded research project SANGUINE to investigate novel approaches to early detection of these blood cancers. It is also bringing together its member societies, patient organisations and other entities to identify precisely what is needed for better blood cancer treatment.

 

Stakeholders from across Europe and beyond joined us as we explored the latest developments in these fields and their potential impact on enhancing blood cancer care.

 

Thank you to all who participated in this valuable event.

11 October 2024 15:00 - 17:00 CEST

Online

SANGUINE Stakeholder Forum Web Banner

Advances in cancer research and biomedical technology have proven crucial in the detection and treatment of blood cancers, saving thousands of lives every year.

The SANGUINE project is building on this effort to develop a quick, minimally invasive, cost-effective, and highly sensitive screening and monitoring tool for blood cancers. It's called the HemaChip. If successful, it would lead to improved patient outcomes, reduced healthcare costs, and enhanced population-based screening programmes.

The European Cancer Organisation is part of the consortium of research organisations, medical institutions, universities and non-profit organisations working on the SANGUINE project. To learn more about the project, visit the official website. 

This digital event brought together leading voices from the cancer community to discuss technological innovations, best practices, and the development of improved public policies aimed at enhancing treatment for blood-related diseases.

Discussion topics included:

  • Improving early detection of blood cancers;
  • Improving the quality of cancer care for haematological malignancies;
  • EU policy and blood cancers.

Participants had the opportunity to hear from experts, exchange ideas, and share their own perspectives in this important conversation.

EN FundedbytheEU RGB POS


Related Resources

Speakers

  • Yuval Ebenstein Professor, Department of Chemical Physics, School of Chemistry, Tel Aviv University
  • John Gribben Professor, Haematologist & Past-President, European Hematology Association
  • Frans Folkvord Co-founder, PredictBy
  • Jesús María Hernández-Rivas Professor in Haematology & Senior Haematologist, Medical University of Salamanca
  • Silene ten Seldam Patient Evidence Research Assistant, Myeloma Patients Europe
  • Eugenia Trigoso Arjona Nurse Coordinator, La Fe Hospital
show all speakers (8)

Speakers

  • Yuval Ebenstein Professor, Department of Chemical Physics, School of Chemistry, Tel Aviv University
  • John Gribben Professor, Haematologist & Past-President, European Hematology Association
  • Frans Folkvord Co-founder, PredictBy
  • Jesús María Hernández-Rivas Professor in Haematology & Senior Haematologist, Medical University of Salamanca
  • Silene ten Seldam Patient Evidence Research Assistant, Myeloma Patients Europe
  • Eugenia Trigoso Arjona Nurse Coordinator, La Fe Hospital
show all speakers (8)
  • Yuval Ebenstein Professor, Department of Chemical Physics, School of Chemistry, Tel Aviv University Read Bio
  • John Gribben Professor, Haematologist & Past-President, European Hematology Association Read Bio
  • Frans Folkvord Co-founder, PredictBy
  • Jesús María Hernández-Rivas Professor in Haematology & Senior Haematologist, Medical University of Salamanca Read Bio
  • Silene ten Seldam Patient Evidence Research Assistant, Myeloma Patients Europe
  • Eugenia Trigoso Arjona Nurse Coordinator, La Fe Hospital Read Bio
  • Solomon Alexis Patient Advocate associated with Myeloma Patients Europe
  • Natacha Bolaños Head of Membership & Alliances for Lymphoma Coalition Read Bio

Speakers

  • Yuval Ebenstein Professor, Department of Chemical Physics, School of Chemistry, Tel Aviv University
  • John Gribben Professor, Haematologist & Past-President, European Hematology Association
  • Frans Folkvord Co-founder, PredictBy
  • Jesús María Hernández-Rivas Professor in Haematology & Senior Haematologist, Medical University of Salamanca
  • Silene ten Seldam Patient Evidence Research Assistant, Myeloma Patients Europe
  • Eugenia Trigoso Arjona Nurse Coordinator, La Fe Hospital
show all speakers (8)

Programme

15:00-15:05
Welcome and introductions  
15:05-15:15
Why blood cancer is different 
 
  • John Gribben, Professor & Past-President, European Hematology Association

SESSION 1: Improving Early Detection of Blood Cancers 
15:15-15:35
Presenting SANGUINE - Preliminary Results and Contribution to Achieving the Objectives of Europe's Beating Cancer Plan
 
  • Yuval Ebenstein, Professor, Department of Chemical Physics, School of Chemistry, Tel Aviv University – SANGUINE Project Overview
  • Frans Folkvord, Co-founder, PredictBy - Stakeholder Engagement Results
15:35-16:05
Stakeholder commentary and response
 
  • Jesús María Hernández-Rivas, Professor in Haematology & Senior Haematologist, Medical University of Salamanca
  • Silene ten Seldam, Patient Evidence Research Assistant, Myeloma Patients Europe

SESSION 2: Improving the Quality of Cancer Care for Haematological Malignancies
16:05-16:15
Presentation of the Essential Requirements of Quality Cancer Care: Haematological Malignancies
 
  • John Gribben, Professor & Past-President, European Hematology Association
16:15-16:35
Stakeholder commentary and response
 
  • Eugenia Trigoso Arjona, Nurse Coordinator, La Fe Hospital & Co-Chair, SIOPE Nursing Working Group
  • Solomon Alexis, Patient Advocate associated with Myeloma Patients Europe

SESSION 3: EU Policy and Blood Cancers
16:35-16:55
Europe's Beating Cancer Plan: Public Policies to Improve Treatment of Blood-related Diseases in Europe
 
  • intervention from the European Commission (TBC)

  • Natacha Bolaños, Head of Membership & Alliances for Lymphoma Coalition – video contribution

CONCLUSIONS
16:55-17:00
Conclusions and next steps

 

Speakers

  • Yuval Ebenstein Professor, Department of Chemical Physics, School of Chemistry, Tel Aviv University
  • John Gribben Professor, Haematologist & Past-President, European Hematology Association
  • Frans Folkvord Co-founder, PredictBy
  • Jesús María Hernández-Rivas Professor in Haematology & Senior Haematologist, Medical University of Salamanca
  • Silene ten Seldam Patient Evidence Research Assistant, Myeloma Patients Europe
  • Eugenia Trigoso Arjona Nurse Coordinator, La Fe Hospital
show all speakers (8)

Speakers

  • Yuval Ebenstein Professor, Department of Chemical Physics, School of Chemistry, Tel Aviv University
  • John Gribben Professor, Haematologist & Past-President, European Hematology Association
  • Frans Folkvord Co-founder, PredictBy
  • Jesús María Hernández-Rivas Professor in Haematology & Senior Haematologist, Medical University of Salamanca
  • Silene ten Seldam Patient Evidence Research Assistant, Myeloma Patients Europe
  • Eugenia Trigoso Arjona Nurse Coordinator, La Fe Hospital
show all speakers (8)